Meeting
2020 ASCO Virtual Scientific Program
Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study.
Authors
Yuankai Shi
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
Yuankai Shi , Xingsheng Hu , Shucai Zhang , Dongqing Lv , Yiping Zhang , Qitao Yu , Lin Wu , Li Liu , Xiang Wang , Zhiyong Ma , Ying Cheng , Hongrui Niu , Dong Wang , Ji Feng Feng , Cheng Huang , Chunling Liu , Hui Zhao , Jingzhang Li , Xiaodong Zhang , Yong Jiang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT 03452592
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9602)
DOI
10.1200/JCO.2020.38.15_suppl.9602
Abstract #
9602
Poster Bd #
368
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
High-dose furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study.
First Author: Haiyang Chen
Poster
2023 ASCO Annual Meeting
A phase 2a study evaluating the efficacy and safety of sutetinib in patients with advanced non–small-cell lung cancer (NSCLC) harboring uncommon EGFR mutations.
First Author: Fengying Wu
Poster
2022 ASCO Annual Meeting
Efficacy and safety of rezivertinib (BPI-7711) in patients with locally advanced or metastatic/recurrent EGFR T790M-mutated NSCLC: A phase IIb, multicenter, single-arm, open-label study.
First Author: Shiman Wu
Poster
2014 ASCO Annual Meeting
E7080 (lenvatinib) in addition to best supportive care (BSC) versus BSC alone in third-line or greater nonsquamous, non-small cell lung cancer (NSCLC).
First Author: Libor Havel